Augmenix, Inc. is pleased to announce the recent opening of a new international headquarters, Augmenix KK., in Japan. The new headquarters is located in central Tokyo and will provide customer support for customers throughout greater Japan.
“We are very pleased with the opening of this new office in Tokyo in anticipation of our SpaceOAR® hydrogel market launch and the Ministry of Health, Labor & Welfare (MHLW) national reimbursement decision by the end of the second quarter in 2018,” said Yoshinori Kuratani, General Manager of Augmenix KK.
“Thanks to our innovative technology and clinical benefits, we have received positive feedback and many inquiries from physicians across Japan interested in adopting SpaceOAR hydrogel. Our continued expansion will enable more physicians in Japan to offer SpaceOAR hydrogel as an option for men with prostate cancer who want to reduce their risk of radiotherapy side effects.”
– Yoshinori Kuratani
General Manager of Augmenix KK.